

# The Theory of Behavioral Change Interventions

**Niamh Ward**

[Niamh.Ward@atlantishealth.com](mailto:Niamh.Ward@atlantishealth.com)

Country Manager, Atlantis Health UK

CONNECTING  
PEOPLE  
SCIENCE AND  
REGULATION®



PDA  
**WORKSHOP**



**Patient Support Programmes (PSPs)  
as Behavior Change Interventions**

**Developing PSPs with  
personalization at their core**

**SMART devices and Behavior Change**

**Integrating SMART devices with  
PSPs**

# Patient Support Programmes (PSPs) as Behavior Change Interventions

# What are Patient Support Programmes (PSPs)?

Patient Support Programmes (PSPs) are designed to maximise the benefit that people receiving a treatment or supportive care for one or more conditions will experience

## Common types of PSP

### Financial assistance

- Varies by market and healthcare system
- Functional and logistical in nature
- On their own, financial assistance programmes do not address other complexities of support needs

### Adherence support

- Primary adherence – does the person pick up their prescription?
- Secondary adherence – does the person take their treatment as agreed with their HCP?
- Persistence – does the person continue on treatment?

### Self-management support

- Improving Health Related Quality of Life
- Supportive behaviors such as exercise and dietary recommendations for the condition
- Target challenges faced by the population, such as low social support, or low mood and high anxiety

PSPs can cover some, or all, of the elements above

# PSPs can effectively address a range of behavioral challenges and stakeholders

RESEARCH

**Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis**

David T. Rubin, MD; Manish Mittal, PhD; Matthew Davis, MA; Scott Johnson, PhD, MHA; Jingdong Chao, PhD; and Martha Skup, PhD

Adv Ther (2018) 35:655–665  
<https://doi.org/10.1007/s12325-018-0706-0>



ORIGINAL RESEARCH

**Is Patient Support Program Participation Associated with Longer Persistence and Improved Adherence Among New Users of Adalimumab? A Retrospective Cohort Study**

Einav Srulovici · Vishvas Garg · Adi Ghilai · Becca Feldman · Moshe Hoshen · Ran D. Balicer · Martha Skup · Maya Leventer-Roberts

**Investigating the Impact of the TUI TEK<sup>®</sup> Patient Support Programme, Designed to Support Caregivers of Children Prescribed Recombinant Human Growth Hormone Treatment in Taiwan**

Pien-Hsia Su<sup>1,2</sup>, Sumaira Malik<sup>3</sup>, Armit Jhoo<sup>4</sup>, Yen-Fan Lin<sup>1</sup>, Su-Huei Su<sup>2</sup>, Ekaterina Kaledova<sup>5</sup> and Selina Graham<sup>6</sup>

British Journal of Health Psychology (2012), 17, 74–84  
 © 2011 The British Psychological Society



[www.wileyonlinelibrary.com](http://www.wileyonlinelibrary.com)

**A text message programme designed to modify patients' illness and treatment beliefs improves self-reported adherence to asthma preventer medication**

Keith J. Petrie<sup>1\*</sup>, Kate Perry<sup>2</sup>, Elizabeth Broadbent<sup>1</sup> and John Weinman<sup>3</sup>

Open access


Original research

BMJ Open  
 Diabetes  
 Research  
 & Care

**Impact of a structured patient support program on adherence and persistence in basal insulin therapy for type 2 diabetes**

Fang Liz Zhou,<sup>1</sup> Jason Yeaw,<sup>2</sup> Swapna U Karkare,<sup>2</sup> Mitch DeKoven,<sup>2</sup> Paulos Berhanu,<sup>1</sup> Timothy Reid<sup>3</sup>

## PSPs can effectively address a range of behavioral challenges and stakeholders



# How can PSPs reach & support patients?

**Comprehensive operational and impact reporting dashboard to monitor and optimise PSP effectiveness**



# Developing PSPs with personalisation at their core




# The science of building effective PSPs


## Providing the right support requires an evidence-based approach

This includes **what** support is provided, **to whom**, **how**, through **which channels**

This is best achieved through a combination of the **scientific literature**, extensive **experience and expertise** and most importantly, **active co-creation** with the stakeholders the support is being designed for



# Personalisation in practice



BEHAVIOURAL FACTOR	EXAMPLE QUESTION	0	10
Treatment beliefs: necessity & concerns	I think the benefits of my treatment will outweigh the drawbacks	Strongly disagree	Strongly agree
Illness knowledge	How well do you feel you understand your condition overall?	Don't understand at all	Understand very clearly
Needle fear / phobia	How anxious do you feel about giving yourself an injection?	Not at all anxious	Extremely anxious

Answers to the questionnaire determine individual support provided:

- Order of online educational topics
- Content of belief-based SMS
- Number of nurse / coaching calls & topics of calls

# Smart devices and Behavior Change



# Using SMART devices to achieve behavior change


## SMART and connected devices are part of a bigger picture

SMART devices are often developed to solve a specific problem, such as tracking adherence, or prompting behaviors. However, to achieve these aims, they usually require **ongoing engagement** from the user, which requires a combination of **knowledge, beliefs, implementation intentions, and habit formation**.

<b>Knowledge</b>	Does the person know how to use the device and connected app?
<b>Beliefs</b>	Will this SMART device help with things that are important to the person using it? Do they perceive there to be downsides to using it? Is it worth the effort?
<b>Implementation intentions</b>	How will the person use the device? When? In what context? Are there existing behaviors that can cue its use?
<b>Habit formation</b>	Is use of the device amenable to becoming habitual? As its use demands less cognitive effort, can it attract the person's attention when it is required?

# Understanding engagement with SMART devices

## The COM-B Model<sup>1</sup>



# Integrating SMART devices with PSPs

# Integrating PSPs and SMART devices

PSPs can be used alongside SMART devices to maximise the benefits of each by:

## Supporting the use of the SMART device itself

- Increasing uptake and adoption of the device
- Increasing engagement with the device and associated app over time
- Helping the individual to integrate the device into their daily life

## Working towards the same behavioural outcome

- Delivering support that aims to reinforce the aims of the SMART device
- Delivering content that is outside of the scope of the device
- Support can be integrated into existing companion apps

## Maximising the use of data

- Helping the user to make the most of data captured and reports generated by the device in their day-to-day life
- Supporting the person and/or their HCP to have productive conversations enabled by data from the device
- Directly using data captured by the device and app, and personalising PSP content provided to the individual

# Example: A PSP and connected inhaler device

## Case Example: CareTRx (pronounced “care tracks”)

### THE CHALLENGE

**The aim:** Improving adherence to maintenance and rescue inhaler use among patients in the UK’s NHS.

**The device:** An inhaler cap that fits to the top of pMDI inhalers and monitors every time the inhaler is used. The cap pairs to an app on the person’s phone, and lets them track the relationship between maintenance and rescue medication use, as well as self-reported symptoms.


### OUR BEHAVIOR CHANGE APPROACH

Through an extensive literature review, and patient and clinician interviews, key beliefs and behaviors associated with two behaviors were identified:

**Non-adherence to treatment,** including underuse of maintenance inhalers, and overuse of rescue inhalers: Included factors like *low necessity and high concerns beliefs about treatment*

**Non-engagement with the device and app:** Included factors such as *low digital self-efficacy*

### THE SOLUTION



**Nurse support: Face-to-face app and device training, and remote coaching**



**eLearning modules providing interactive behavior change interventions**



**Nudge-based in-app messages and emails reinforcing behavior change**

A nurse led service introduced new patient users to the device and app as part of a lung health assessment.

Once using the system, patient support including online eLearning modules, in-app notifications, and emails, would help address both causes of non-adherence to recommended treatment, and non-engagement with the device and app.

### THE IMPACT

#### The Programme delivered:

NHS TestBed respiratory connected device ecosystem demonstrated:


- ▲ A proven adherence uplift of 47% and persistence to the intervention was at 78% over 1 year in moderate to severe asthma



# Example: CareTRx

What support could each patient cluster receive?

- Depending on their needs, patients may receive an additional call in week 4 of the programme, to ensure they are comfortable using CareTRx™.
- When visiting the CareTRx™ website, each patient will see the content that is most relevant to them.



# Example: Connected devices in Growth Hormone Disorder

## Case Example: TuiTek Patient Support Programme, Easypod autoinjector, & Growlink app

### THE CHALLENGE

Up to 82% of children and adolescents treated with r-hGH therapy and their families were non-adherent to treatment.<sup>1</sup>

**The aim:** Personalise caregiver support to address their individually identified behavior and practical risks to medication adherence

**The device:** An automated electronic autoinjector with a transmitter and web-based connection platform.

### OUR BEHAVIOUR CHANGE APPROACH

Atlantis Health's behavioral modeling identified four key factors impacting adherence of patients receiving r-hGH treatment:

- Disease and treatment coherence
- Emotional burden of disease
- Treatment-related anxiety
- Self-administration self-efficacy

### THE SOLUTION



**Nurse support: Personalised nurse support calls**



**Connected autoinjector & web / mobile apps for tracking adherence & growth**

Nurse-led support programme to caregivers of children receiving r-hGH in a country where poor adherence was reported as being particularly problematic<sup>1</sup>

The device allows for automatic recording, storage, and transmission of drug adherence, and self-reported growth. This information can be accessed via a patient app, and physicians and nurses can access the information via the web platform.

### THE IMPACT

#### The Programme delivered:

- ▲ All 'high risk of non-adherence' caregivers at baseline moved into the 'low risk' category across all targeted behavioral factors
- ▲ For example, out of 40 caregivers, a 30% reduction in treatment-related anxiety was observed
- ▲ Results papers published in peer reviewed endocrinology journals<sup>2,3,4</sup>



Thanks for listening!